Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Reduced MBF Regimen for Patients Over 50 Years With Myeloid Malignancies

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan

  • 0 views
  • 04 Oct, 2022
  • 2 locations
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed

cancer
cell transplantation
daratumumab
diffusion capacity of the lung for carbon monoxide
mycophenolate mofetil
  • 0 views
  • 29 Mar, 2021
  • 1 location
Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft Versus-host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation

The purpose of this study is to determine the response and toxicity rate of two different dosages (Individualized dosage VS. fixed dosage) of ATG as a prophylaxis for acute GVHD in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT).

  • 0 views
  • 15 Oct, 2022
  • 1 location
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity

idarubicin
blast cells
neoadjuvant therapy
anthracyclines
fludarabine
  • 0 views
  • 26 Jan, 2022
  • 69 locations
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (RIC)

This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant

cyclosporine
histiocytosis
shortening fraction
fludarabine
melphalan
  • 1 views
  • 08 Apr, 2022
  • 1 location
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC)

The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to …

  • 22 views
  • 28 May, 2022
  • 1 location
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

pulse oximetry
graft versus host disease
graft-versus-host disease
malignant disease
fludarabine
  • 18 views
  • 07 Mar, 2022
  • 2 locations
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell transplants. The researchers will compare two different drug combinations used to reduce the risk of a …

waldenstrom's macroglobulinemia
pentostatin
cancer
ibrutinib
stem cell transplantation
  • 64 views
  • 05 Jun, 2022
  • 1 location
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other …

solid tumor
chronic lymphocytic leukemia
hematologic disorder
tumor cells
melphalan
  • 0 views
  • 21 Apr, 2022
  • 1 location
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with

cell transplantation
blood disorder
cytopenia
fludarabine
chest syndrome
  • 10 views
  • 04 Jun, 2022
  • 1 location